SMMT240920P50000
- 19.20
- 0.000.00%
Summit Therapeutics Newsroom
US stocks mining | The Federal Reserve cuts interest rates more than expected! Multiple real estate-related stocks reach new highs for the year; Accelerate the acquisition plan, US private equity giant KKR rises more than 9% in five days
Soft landing expected to ignite! ai optical communication company Coherent rose nearly 4% on the previous trading day, with a cumulative increase of nearly 90% within the year; ai cloud computing service platform servicenow hit another historical high intraday, with a total annual increase of over 26%.
Is It Too Late to Buy Summit Therapeutics Stock After Its Almost 10X Gain This Year?
Bullish on US stocks | More policy support! Li Auto Inc. jumped over 12% overnight; Rate cut expectations boost credit card companies to hit new historical highs.
Heavy investment! Blackrock joined hands with Microsoft to bet on the AI track, reaching the $900 mark overnight and hitting a new historical high, with a 1.04% increase; target price was raised by major bank analysts! Applovin, a mobile advertising technology company, soared more than 6% overnight, surging more than 40% in the past 5 trading days, and has risen more than 200% so far this year, creating a new historical high again.
Trending Stocks Today | Galmed Pharmaceuticals Soars 416.53%
September 17th - US stocks trending in regular trading hours.Gainers: $Galmed Pharmaceuticals(GLMD.US)$ shoots up 416.53% to $19.99 with a turnover of $1.08 billion. $BurgerFi International(BFI.US)$
BioNTech Raised to Buy at Jefferies on New Cancer Drug
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $45
H.C. Wainwright analyst Mitchell Kapoor maintains $Summit Therapeutics(SMMT.US)$ with a buy rating, and maintains the target price at $45.According to TipRanks data, the analyst has a success rate
A 160% surge in a week, one good medicine is enough to change fate! What is summit therapeutics (SMMT.US)?
In the US stock market last week, a stock called Summit Therapeutics (SMMT.US) rose unexpectedly, not only surging 160% itself, but also lifting biotechnology companies such as BioNTech and Instil Bio along with it.
Summit Therapeutics Reports High Response Rates From Ivonescimab Trials in Cancer Studies
Alphabet To $200? Here Are 10 Top Analyst Forecasts For Monday
Insider Buying: Summit Therapeutics Co-CEO & Executive Chairman Bought US$75m Of Shares
Robert Duggan Buys Handful Of Shares In Summit Therapeutics
Summit Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Summit Therapeutics Analyst Ratings
Summit Therapeutics Says Ivonescimab Data Were Presented At 2024 ESMO Annual Meeting, Including Two Presentations And One Poster Featuring Updated Ivonescimab Data In Advanced Triple-negative Breast Cancer, Recurrent/Metastatic Head And Neck Squamous...
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Raises Target Price to $45
H.C. Wainwright analyst Mitchell Kapoor maintains $Summit Therapeutics(SMMT.US)$ with a buy rating, and adjusts the target price from $30 to $45.According to TipRanks data, the analyst has a success
Express News | Summit Therapeutics PLC : H.c. Wainwright Raises Target Price to $45 From $30
The increase within the year reached 1123%! The cooperation between Chinese and American pharmaceutical companies defeated the "global pharmaceutical king", and the CEO said straightforwardly, "We are on the right side".
Summit Pharmaceuticals has surpassed the global drug king pembrolizumab from China's pharmaceutical company Akeso with its new drug Yervoy (PD-1/VEGF bispecific antibody) in a head-to-head clinical trial.
Chewy, Broadcom And MicroStrategy Are Among Top 10 Large Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?
Is Summit Therapeutics Inc. (NASDAQ:SMMT) an Unstoppable Growth Stock To Buy Now?